The approval and use of the BCL-2:BIM complex-disrupting Venetoclax has heightened interest in finding precision medicine tools that could measure priming and, in doing this, identify cancer cells dependencies as vulnerabilities that could be addressed with therapy. The gene discussed is BCL2; the disease is cancer.